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Comparison of two region of interest definition methods
for metabolic response evaluation with [18F]FDG-PET
D. VRIENS 1, L. F. DE GEUS-OEI 1, H. W. M. VAN LAARHOVEN 2,
H. F. M. VAN DER HEIJDEN 3, P. F. M. KRABBE 4, E. P. VISSER 1, W. J. G. OYEN 1
Aim. In therapy response monitoring by [18F]2-fluoro-2-
deoxy-D-glucose positron emission tomography (FDG-
PET), different tumor delineations are used, resulting
in different values for change in glucose metabolic rate
(∆MRglu). We propose a technique to compare metabol-
ic rates in a region of interest (ROI) based on fixed vol-
umes rather than on fixed thresholds. This method
involves change in lesion size.
Methods. In 49 patients with colorectal carcinoma (CRC)
and 50 patients with non-small cell lung carcinoma
(NSCLC) scheduled for chemotherapy, FDG-PET was
performed at baseline and during chemotherapy. A
ROIfixed thresholds was determined by using a 50% thresh-
old on both baseline and follow-up FDG-PET. A ROIfixed
volumes was determined by using a 50% threshold, deter-
mined on the series with the largest tumor volume. This
ROIfixed volumes is used on consecutive scans. Predictive
effects of both methods were investigated by survival
analysis for overall and progression free survival.
Results. In CRC, only ROIfixed volumes based ∆MRglu
showed significant predictive ability. In NSCLC, both
techniques showed significant predictive ability. During
multivariate analysis, ROIfixed volumes determined ∆MRglu
was an independent predictor for both overall and pro-
gression free survival in NSCLC whereas ROIfixed thresh-
olds determined MRglu was not. After dichotomization at
the median ∆MRglu, median survival ratio was higher in
ROIfixed volumes than ROIfixed thresholds for CRC (overall
survival: 1.78 vs 1.25, progression free survival: 1.57 vs
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1.21) and NSCLC (overall survival: 2.01 vs 2.01, pro-
gression free survival: 2.93 vs 2.13).
Conclusion. ROIfixed volumes based ∆MRglu shows better
correlation with survival than ∆MRglu determined from
a ROIfixed thresholds.
KEY WORDS: Colorectal carcinoma - Non-small cell lung car-
cinoma - [18F]FDG - Positron emission tomography -
Chemotherapy - Drug monitoring - Survival - Neoplasms,
therapy.
Functional imaging with [18F]2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET)
has an established role in the standard care for patients
with colorectal carcinoma (CRC) or non-small cell
lung carcinoma (NSCLC) by staging of the disease.
Growing interest in the application of FDG-PET for
prediction and evaluation of tumor response to ther-
apy has risen, since morphologic imaging techniques
such as computed tomography (CT) or magnetic res-
onance imaging (MRI) may lead to incorrect conclu-
sions about therapy response. Due to the fact that it
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proves difficult to reliably distinguish between thera-
py induced fibrosis, tumor necrosis and recurrent or
residual tumor in both CRC 1-3 and NSCLC,4 favorable
and adverse alterations may be indistinguishable.
Furthermore, metabolic changes in tumor cells, indica-
tive of response to therapy, may occur earlier than
changes in lesion size,5 especially as some new anti-
tumor therapies are cytostatic rather than cytoreduc-
tive. Early detection of tumor progression during
chemotherapy by FDG-PET might therefore prevent
unbeneficial, perhaps even harmful treatment.
It has already been demonstrated that pre- and
post-therapy parameters for tumor glucose metabolism
are of prognostic value in CRC 6 and NSCLC.7-11 In
addition, changes in the rate of glucose metabolism
predict overall and progression-free survival in both
CRC 12 and NSCLC.8-11, 13
Since the value of change in glucose metabolic
activity is highly dependent on the definition of tumor
volume of interest (region of interest [ROI]), an exact
and reproducible definition of ROI methodology is
important.14-16 Institution-dependent ROI definitions
may lead to variations in the classification of metabolic
response and may hinder the integrated or compara-
tive interpretation of results of multiple centers. In
literature, many different methods have been used to
define tumor ROI: a thresholded 3D isocontour (using
50% or 70% of the maximum voxel value within the
lesion), the maximum voxel value or a fixed dimen-
sions-method (e.g. 15×15 mm2 around maximum val-
ue).14 The first method determines treatment induced
changes in tumor metabolic activity in two different
volumes, since using fixed thresholds, glucose meta-
bolic rate (MRglu) is determined in the metabolic active
volume only.
The use of the fixed thresholds-based methodolo-
gy is attractive since tumor delineation on FDG-PET
is practical, easier to perform and more reproducible
than other methods. A disadvantage of the fixed
thresholds technique is that the threshold level is cho-
sen rather arbitrarily and that only MRglu in residual,
metabolic active tumor is taken into account. As a
result, a lesion that decreases in size, but preserves the
same baseline metabolic activity will not be considered
to respond to treatment with this ROI-definition.
Moreover, a sole decrease in lesion volume might
artifactually decrease the measured metabolic activi-
ty due to the partial-volumes effect,14 especially in
case of residual tumor less than ~15 mm in diameter.
When using the same ROI during treatment response
assessment (fixed volumes), both the change in meta-
bolic activity as well as the change in tumor meta-
bolic volume are taken into account. Since a decrease
in lesion volume causes peritumoral tissue with nor-
malized FDG accumulation that is incorporated in the
ROI resulting in a reduction of its MRglu.
The hypothesis is that using the same ROI-volume
for MRglu determination, both at baseline and during
follow-up is more indicative for therapy response.
Present study introduces two distinct ROI methods
for metabolic response evaluation assessed prospec-
tively in both CRC and NSCLC patients. One tech-
nique solely evaluates metabolic response and the
other incorporates the change in volume. Both tech-
niques are correlated with patient survival.
Materials and methods
Patient eligibility criteria
Between March 2002 and December 2005 patients
in the Radboud University, Nijmegen Medical Center
with metastatic CRC (stage IV), who were scheduled
to undergo palliative chemotherapy and patients with
any stage of NSCLC, who were scheduled to undergo
induction chemotherapy or palliative chemotherapy
were asked to participate in this study. Exclusion cri-
teria were diabetes mellitus and pregnancy.
In all patients, treatment decision-making was done
by a multidisciplinary team including medical oncol-
ogists, surgeons (CRC), cardiothoracic surgeons
(NSCLC), pulmonologists (NSCLC), radiation oncolo-
gists, pathologists, radiologists and nuclear medicine
physicians. All clinicians were blinded to the results
of the serial FDG-PET scans. The study was approved
by the Institutional Review Board of the Radboud
University, Nijmegen Medical Center and written
informed consent was obtained from each patient.
One hundred and twenty-one consecutive eligible
patients could be included in this prospective study (61
advanced CRC, 60 NSCLC). After the baseline FDG-
PET, 22 patients (12 CRC, 10 NSCLC) were excluded
for several reasons: due to technical issues (n=4),
refusal to undergo a second FDG-PET (n=5), death
before the second FDG-PET (n=3) and early discon-
tinuation of chemotherapy due to a significant decline
in performance status (n=10). Therefore, complete
data-sets of two FDG-PET were available in 99 patients
(49 CRC and 50 NSCLC) for analysis of therapy
response. Patient characteristics for both tumor types
are summarized in Tables I and II.
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Patient treatment
Of the CRC patients, 26 patients received first line
chemotherapy, 16 in second line, 6 in third line and
1 in fourth line. Chemotherapy regimens were based
on fluoropyrimidines (capecitabine and 5-fluorouracil)
with or without oxaliplatin and irinotecan or mono-
clonal antibodies (bevacizumab and cetuximab).
Of the NSCLC patients, 14 patients were treated
with induction chemotherapy and the remaining 36
received chemotherapy in a palliative setting (32 in first
line and 4 in second line). Chemotherapy regimens
were based on platinum-containing alkylating agents,
gemcitabine, etoposide, vinorelbine or docetaxel.
Patients receiving induction chemotherapy were sub-
sequently treated with radical radiotherapy (n=9) or
curative surgery (n=2). The remaining 3 patients were
treated with palliative radiotherapy, because of pro-
gression during induction chemotherapy based on
CT-criteria.
No patients were lost during follow up. Survival of
patients is displayed in Table III.
[18F]2-fluoro-2-deoxy-D-glucose positron emission
tomography
QUANTITATIVE DYNAMIC FDG-PET DATA ACQUISITION AND
RECONSTRUCTION
Dynamic FDG-PET was performed at baseline and
after 2 months of treatment (CRC) or after the sec-
ond or third cycle of chemotherapy (NSCLC), depend-
ing on the chemotherapy regimen. Patients were fast-
ed for at least 6 h before imaging. Intake of sugar-free
liquids was permitted. Blood glucose levels (hexok-
inase method, Aeroset, Abbott diagnostics, IL, USA)
were determined. All scans were acquired on an
ECAT-EXACT47 PET scanner (Siemens/CTI, Knoxville,
TN, USA). The position of the patient in the scanner’s
field of view (162 mm in 47 planes) for dynamic acqui-
sition was based on the whole-body FDG-PET and CT
scans performed in every patient for routine clinical
work-up. In case not all lesions could be acquired in
TABLE I.—Characteristics of patients with colorectal carcinoma.
Characteristics CRC
Demography
No. of patients 49
Mean age (y) (range) 60.5 (44.7-78.9)
Men (%) 36 (73.5%)
Location of primary tumor
Colon 10
Sigmoid 23
Rectum 9
Colon and rectum 7
Location of metastases
Liver 42
Lung 15
(Retro) peritoneal lymph nodes 4
Bone 2
Histology
Adenocarcinoma 46
Mucinous adenocarcinoma 3
Tumor differentiation
Undifferentiated 1
Very poor 2
Poor 5
Intermediate 31
Well 2
Unspecified 8
CRC: colorectal carcinoma.
TABLE II.—Characteristics of patients with non-small cell lung
carcinoma.
Characteristics NSCLC
Demography
No. of patients 50
Mean age (y) (range) 59.7 (41.2-76.3)
Men (%) 37 (74%)
Histology
Adenocarcinoma 23
Squamous cell carcinoma 21
Large cell carcinoma 4
Bronchoalveolar cell carcinoma 1
Clear cell carcinoma 1
Tumor differentiation
Very poor 12
Poor 6
Intermediate 7
Well 1
Unspecified 24
Tumor stage at inclusion
I 1 (B)
II 1 (A)
III 8 (A); 9 (B)
IV 31
NSCLC: non-small cell lung carcinoma.
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one field of view, the patient was positioned to
include as many measurable tumor lesions as pos-
sible. This position was used for follow-up scan-
ning as well. A 20-min transmission scan was made,
using the internal 68Ge/68Ga sources, to correct for
photon attenuation. Approximately 200 MBq FDG
(Covidien, Petten, the Netherlands) was injected
intravenously using a constant infusion remote-con-
trolled pump (Medrad, Indianola, PA, USA). The
dynamic data acquisition, performed in septa-
extended (two-dimensional) mode, was started
simultaneously with the injection of FDG and con-
Figure 1.⎯Example of different ROI-definitions with FDG-PET in a 70-year-old male patient with squamous cell NSCLC, T2N2M1 treated with
two cycles of first line carboplatin/gemcitabine chemotherapy. Planes were anatomically correlated. ∆MRglu for fixed thresholds was -54%
and for fixed volumes -82%. Patient was alive after 3 years of treatment. A, B) ROIfixed volumes; C, D) ROIfixed thresholds. ROI: region of interest;
FDG-PET: [18F]2-fluoro-2-deoxy-D-glucose positron emission tomography; NSCLC: non-small cell lung carcinoma; ∆MRglu: relative change in
glucose metabolic rate between baseline and follow-up FDG-PET.
TABLE III.—Outcome of follow-up of CRC and NSCLC patients using Kaplan-Meier analysis.
Event-free Median (CI) 1 year (CI) 2 year (CI) 3 year (CI)
N. (%) (weeks) (%) (%) (%)
CRC
Overall survival 8 (16) 89 (74-104) 78 (66-89) 38 (24-52) 16 (5-27)
Progression free survival 1 (2) 25 (21-30) 18 (8-29) 4 (0-10) 2 (0-6)
NSCLC
Overall survival 7 (14) 58 (25-91) 56 (42-70) 36 (23-49) 22 (10-34)
Progression free survival 3 (6) 26 (14-39) 27 (14-39) 17 (6-27) 8 (0-16)
CRC: colorectal carcinoma; NSCLC: non-small cell lung carcinoma. CI: 95% confidence interval.
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sisted of 16 time frames with variable duration
(10×30 s, 3×300 s, 3×600 s) for a total time of 50
min. Corrections for decay, randoms, and scatters
was performed. Attenuation-corrected images were
reconstructed in 128×128×47 matrices, using filtered
back projection with a Gaussian filter of 4 mm full
width at half maximum (FWHM). This resulted in
voxels of 3.432×3.432×3.375 mm (39.8 µL) and a
spatial resolution of 6 mm FWHM in the recon-
structed images.
PLASMA TIME-ACTIVITY CURVES
Plasma time-activity curves were derived from 17
manually taken arterial blood samples (~2 mL) from
a 20-G cannula in the radial artery. Seven samples
were drawn at 15-s intervals, followed by samples at
135 s, 165 s, 225 s, 285 s, 7.5 min, 12.5 min, 17.5 min,
25 min, 35 min, and 45 min after injection.
Radioactivity in the plasma (obtained by centrifuga-
tion) was determined in a well-type γ-counter (Wallac
1480 Wizard, Perkin Elmer Lifescience, Zaventem,
Belgium). This procedure is extensively described
before.17 When arterial cannulation was contraindi-
cated or not feasible (in 44 of 98 CRC scans and 41 of
100 NSCLC scans), an image-derived input function
(IDIF) was determined by measuring FDG-counts in
a ROI over the ascending aorta or the abdominal aor-
ta, that accurately represents FDG blood levels.17
TUMOR TIME-ACTIVITY CURVES AND REGION OF INTEREST
METHODOLOGY (FIXED THRESHOLDS, FIXED VOLUMES)
Tumor time-activity curves were obtained by plac-
ing 3D ROIs over the tumor and each metastasis using
two different techniques: the fixed thresholds and
fixed volumes method. The locations of the lesions
were evaluated visually on the transaxial, coronal and
sagittal images in summed late time frames (frame
14-16) yielding a static image of 30 min and a scan
mid-time of 35 min postinjection.
The ROIfixed thresholds were semi-automatically deter-
mined using an isocontour with a threshold of 50% of
the maximum voxel value within the lesion on the
pretreatment scan. This ROIfixed thresholds was copied to
each time frame of the scan. This process was repeat-
ed on the follow-up scan (Figures 1A and 1B). In case
of complete metabolic response, which implies that no
tumor contour could be determined by a certain
threshold, the ROI of the baseline scan was copied.
Thereby, the ROI included ‘background’ tissue with
the same FDG uptake as surrounding tissue (liver or
lung).
The ROIfixed volumes were semi-automatically deter-
mined using isocontours with a threshold of 50% of the
maximum voxel value within the lesion on the FDG-
PET on which the lesion was largest. In case of par-
tial or complete metabolic response (decrease of
threshold based volume) the ROIfixed volumes was deter-
mined on the pretreatment FDG-PET and copied to the
second FDG-PET and in case of progressive disease
(increase of threshold based volume or appearance of
new lesions) the ROIfixed volumes was determined on the
second FDG-PET and copied to the pretreatment
FDG-PET. The copied ROI was manually translated in
all three-dimensions using anatomical landmarks of
surrounding structures. This ROIfixed volumes was used on
each time frame of the scan (Figures 1C and 1D).
PATLAK ANALYSIS
Patlak analysis was used to compute the MRglu (in
µmol.mL-1.min-1) in each lesion using both ROIs and
the plasma time-activity curve (or IDIF), as described
in detail.17, 18 MRglu in the ROI was calculated by mul-
tiplication of the slope of the Patlak-plot with the
blood glucose level. When multiple lesions were
quantified in one patient, mean MRglu was calculated
weighting every lesion by its ROI volume by the equa-
tion:
The relative change in MRglu (∆MRglu) between the
baseline and follow-up FDG-PET was calculated
(∆MRglu=[MRglu, follow-up-MRglu, baseline].[MRglu, baseline]-1.
100%).
CLINICAL FOLLOW-UP
During and after treatment, patients were followed
with clinical examination at regular intervals, chest
CTs (NSCLC, every 6 months in CRC), abdominal
CT/MRI (every 3 months in CRC), chest X-rays
(NSCLC), CEA measurement (CRC), routine laborato-
ry tests and other imaging studies as clinically indi-
cated. Morphologic tumor response was evaluated
on CT, MRI or conventional chest X-ray according to
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response evaluation criteria in solid tumors (RECIST)
19 without knowledge of the results of the FDG-PET
studies. These criteria define progression as a 20%
increase in the sum of longest diameters of target
lesions or the appearance of new lesion.19 When
recurrence was suspected or proven, patients were
always re-staged. The progression and relapse pat-
tern and cause of death were determined in all cases.
The date of local or distant progression was defined
as the earliest date at which disease progression was
confirmed, either clinically or by imaging or biopsy.
In patients who were progression free at the closeout
date (April 2008) or who had died from any cause, the
time to progression was censored at that date. Survival
was measured from the date of the baseline FDG-
PET scan to the date of death. In patients who were
alive at the closeout date survival was censored to
that date.
Statistical analysis
All continuous variables were assessed for nor-
mality by the Shapiro-Wilk statistic. For non-normal
distributions, median and interquartile range (IQR)
are presented as measures for central tendency and
dispersion, the non-parametric Wilcoxon signed ranks
test was used for comparison and correlation between
both ROI methods is displayed as Spearman’s ρ.
Metabolic rate changes during therapy were classi-
fied as reduced (∆MRglu <-20%), increased (∆MRglu
>+20%) or stable (-20% ≤∆MRglu ≤+20%). These cut-
offs were based on the test-retest reproducibility of
MRglu which has a 95%-confidence interval of around
±15-20%.16, 20
Overall survival and progression free survival served
as the standard of reference. The overall and pro-
gression free survival with respect to the different
∆MRglu were calculated using Kaplan-Meier analysis.
Cox’s proportional hazards model was used to
assess the predictive value of response evaluation
with FDG-PET, as expressed in the ∆MRglu between
the FDG-PET at baseline and at follow-up. As can-
didate covariates patient age, sex and tumor staging
(NSCLC) are used in a forward model based on like-
lihood ratios (P<0.05 for covariate entry, P>0.1 for
covariate removal). Hazard ratios (HR) are present-
ed, representing the ratio of odds that a metabolic
responder will survive a certain amount of time
compared to a metabolic non-responder. Statistical
significance of each model parameter was assessed
using Wald’s χ2 test. As a measure of time-to-effect,
both median survival times and their ratio (median
ratio) are presented, assessed using the log rank
test. As cut-off median ∆MRglu was chosen to avoid
the effect that expected lower values for fixed vol-
umes-determined ∆MRglu account for differences.
The median ratios present the ratio of time that 50%
of the metabolic responder will survive compared to
the time 50% of metabolic non-responder survive.21
Finally, another cut-off for ∆MRglu was used for
which >90% of the patients show 1-year overall sur-
vival to investigate how a prognosis-driven thresh-
old (as contrast to metabolic response-driven thresh-
old) might prove of additional value.
Analysis was performed with the Statistical Package
for Social Sciences (SPSS®) version 14.0.2 (SPSS Inc,
Chicago, IL, USA) and GraphPad Prism version 5.0a
(GraphPad Software, La Jolla, CA, USA). Statistical
tests were based on a two-sided significance level
and the level of significance was set at P=0.05 for all
tests.
Results
Quantitative changes in [18F]2-fluoro-2-deoxy-D-glu-
cose positron emission tomography uptake
Median interval between baseline and follow-up
FDG-PET was 63 days (IQR: 55-68) in the CRC-group
and 48.5 days (IQR: 41-60) in the NSCLC-group. Bland-
Altman plots 22 of ∆MRglu of both ROI-definitions and
both cancer types are displayed in Figure 2. In both
CRC and NSCLC the decline in median of all MRglu
between first and second FDG-PET was statistically sig-
nificant (P<0.001). Median ∆MRglu for ROIfixed thresholds
was -29.6% versus -51.9% for ROIfixed volumes in CRC
patients (P=0.01). Median ∆MRglu for ROIfixed thresholds
was -37% versus -50% for ROIfixed volumes in NSCLC
patients (P=0.01). The difference in ∆MRglu based on
both ROI-methods varied from -232% to +107% (CRC)
and from -29% to +172% (NSCLC). Outliers were espe-
cially seen when ROI-volumes assessed by ROIfixed
thresholds were small, rendering their MRglu more sensi-
tive to noise. According to previously mentioned def-
initions of response in MRglu from ROIfixed volumes, 33 of
49 CRC patients showed reduction in metabolism, 7
showed increase in metabolism and the remaining 9
showed stable metabolism. In 36 of 49 cases, con-
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clusions about change in metabolism were concordant.
In NSCLC, 35 of 50 patients showed reduction in
metabolism, 6 showed increase in metabolism and
the remaining 9 showed stable metabolism. In 45 of
50 cases, conclusions about change in metabolism
were concordant. Differences between the two ROI-
methods are displayed in Tables IV and V. Correlation
between ∆MRglu in ROIfixed thresholds and ROIfixed volumes
was 0.879 (CRC) and 0.932 (NSCLC) (both P<0.001).
Prediction of survival by [18F]2-fluoro-2-deoxy-D-glu-
cose positron emission tomography
Cox proportional hazards model for CRC showed
significant predictive ability of overall and progression
free survival only for ∆MRglu in ROIfixed volumes between
baseline and second FDG-PET. No contributing con-
founders were found in the candidate covariates (Table
VI).
The same type of analysis was used for NSCLC and
showed significance predictive ability for overall as
well as for progression free survival for both ∆MRglu
calculated in ROIfixed volumes and ROIfixed thresholds (Table
VI). Tumor staging showed strong predictive value
in univariate analysis (HR 1.723 in overall survival
and 1.942 in progression free survival). 
Only tumor stage was found to be a significant con-
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Figure 2.—Bland-Altman plots for both cancer types. The means of ∆MRglu of both ROI-techniques (x-axis) and difference between ∆MRglu
of ROI-techniques (y-axis) are displayed. The solid line states the mean difference; the dotted lines the mean±2 standard deviations. NSCLC:
non-small cell lung carcinoma; CRC: colorectal carcinoma; ROI: region of interest; ∆MRglu: relative change in glucose metabolic rate between
baseline and follow-up FDG-PET.
TABLE IV.—Number of colorectal cancer patients with decrea-
sed (∆MRglu<-20%), stable (-20≤∆MRglu≤+20%) or increased
(∆MRglu>+20%) metabolism based on both ROI-definitions.
∆MRglu, fixed thresholds
Decreased Stable Increased Total
Decreased 26 7 0 33
∆MRglu, fixed volumes
Stable 2 6 1 9
Increased 0 3 4 7
Total 28 16 5 49
∆MRglu: change in glucose metabolic rate between baseline and follow-
up scan; ROI: region of interest.
TABLE V.—Number of non-small cell lung carcinoma patients
with decreased (∆MRglu <-20%), stable (-20≤∆MRglu ≤+20%)
or increased (∆MRglu >+20%) metabolism based on both ROI-
definitions.
∆MRglu, fixed thresholds
Decreased Stable Increased Total
Decreased 32 3 0 35
∆MRglu, fixed volumes
Stable 1 8 0 9
Increased 0 1 5 6
Total 33 12 5 50
∆MRglu: change in glucose metabolic rate between baseline and follow-
up scan; ROI: region of interest.
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founding covariate in NSCLC in multivariate Cox pro-
portional hazards analysis. After correction for this con-
founder, only ∆MRglu calculated from a ROIfixed volumes
showed significant predictive value for both overall and
progression free survival. ROIfixed thresholds based ∆MRglu
from showed significant prediction of only overall sur-
vival after correction for tumor stage (Table VII).
Using medians as cut-offs shows that the median
ratio for overall survival in CRC was 1.78 (HR: 2.02;
P=0.03) in ROIfixed volumes and 1.25 in ROIfixed thresholds
(HR: 1.75; P=0.082). For progression free survival the
median ratio is 1.57 (HR: 1.24; P=0.294) and 1.21 (HR:
1.23; P=0.384), respectively. In NSCLC the median
ratio for overall survival is 2.01 (HR 2.17; P=0.012) in
ROIfixed volumes and 2.01 in ROIfixed thresholds (HR: 2.19;
P=0.01) and for progression free survival 2.93 (HR:
2.02; P=0.015) and 2.94 (HR: 2.13; P=0.009).
In CRC, a ∆MRglu of -50% in fixed volumes and -34%
in fixed thresholds separates patients who have 90%
1-year overall survival from those with lower overall
survival rates. In NSCLC, these values are -67% for
fixed volumes and -64% for fixed thresholds. In
NSCLC, this is highly different from the medians. Using
these values for prognosis-driven cut-offs in patients
with NSCLC instead of the median value, the median
ratio for overall survival was 4.81 (HR: 5.5; P<0.001)
in ROIfixed volumes and 4.51 in ROIfixed thresholds (HR: 3.68;
P=0.008). These cut-offs separate the 18-20% of best
responding patients from the rest. Results are pre-
sented in Figure 3.
TABLE VI.—Results of univariate Cox proportional hazards regression analysis for overall and progression free survival using
∆MRglu between the FDG-PET-scan at baseline and follow-up.
Overall survival Progression free survival
Hazard ratio CI P** Hazard ratio CI P**
CRC
ROIfixed volumes ∆MRglu* 1.026 1.001-1.051 0.04° 1.040 1.009-1.071 0.01°0
ROIfixed thresholds ∆MRglu* 1.014 0.987-1.042 0.302 1.023 0.993-1.055 0.13°0
Sex 0.959 0.479-1.923 0.907 0.992 0.519-1.897 0.982°0
Age 0.976 0.936-1.016 0.237 0.975 0.938-1.014 0.207°0
NSCLC
ROIfixed volumes ∆MRglu* 1.069 1.024-1.116 0.002° 1.100 1.044-1.16 <0.001°
ROIfixed thresholds ∆MRglu* 1.133 1.046-1.227 0.002° 1.136 1.048-1.232 0.002°
Stage 1.723 1.204-2.467 0.003° 1.942 1.327-2.841 0.001°
Sex 1.142 0.557-2.342 0.718 1.162 0.61-2.212 0.647°
Age 1.009 0.975-1.043 0.608 0.984 0.952-1.017 0.341°
*Per 10% change; **Wald’s χ2 test; °significant at the 0.05 level. ∆MRglu: relative change in glucose metabolic rate between baseline and follow-up FDG-
PET; CRC: colorectal carcinoma; NSCLC: non-small cell lung carcinoma. ROI: region of interest; FDG-PET: [18F]2-fluoro-2-deoxy-D-glucose positron emission
tomography; CI: 95%-confidence interval.
TABLE VII.—Results of multivariate Cox proportional hazards regression analysis for overall and progression free survival using ∆MRglu
between the FDG-PET-scan at baseline and follow-up. 
Overall survival Progression free survival
Hazard ratio CI P** Hazard ratio CI P**
ROIfixed volumes ∆MRglu* 1.051 1.004-1.1 0.034° 1.073 1.014-1.135 0.003°
Stage 1.624 1.129-2.337 0.009° 1.769 1.208-2.593 0.015°
ROIfixed thresholds ∆MRglu* 1.091 1.003-1.187 0.043° — — —
Stage 1.581 1.093-2.287 0.015° 1.942 1.327-2.841 0.001°
*Per 10% change; **Wald’s χ2 test; °significant at the 0.05 level. ∆MRglu: relative change in glucose metabolic rate between baseline and follow-up FDG-
PET; NSCLC: non-small cell lung carcinoma. ROI: region of interest; FDG-PET: [18F]2-fluoro-2-deoxy-D-glucose positron emission tomography; CI: 95%-con-
fidence interval.
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Figure 3.—Kaplan-Meier survival curves for overall survival in CRC patients. ∆MRglu are dichotomized by the cut-off where 90% of the meta-
bolic responders have 1-year overall survival. CRC: colorectal carcinoma; NSCLC: non-small cell lung carcinoma; FDG-PET: [18F]2-fluoro-2-
deoxy-D-glucose positron emission tomography; ∆MRglu: relative change in glucose metabolic rate between baseline and follow-up FDG-
PET; HR: hazard ratio [95% confidence interval].
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Discussion
Fluorine-18-FDG-PET is a promising imaging modal-
ity for therapy response assessment. The variety of
analytical methods is vast, thus multicenter research
is hardly feasible. For that, standardization of acqui-
sition, reconstruction, ROI-determination and SUV-
normalization needs to be accomplished.15, 23 In the
present study, two methods for determination of ROIs,
used for Patlak MRglu-estimations, were compared
using survival as primary outcome measure. Only a
small number of studies have addressed the effect of
ROI-definition on FDG uptake,14-16 mostly using stan-
dardized uptake value (SUV) instead of the gold stan-
dard MRglu, of which is known that high correlations
exist for both CRC 12 and NSCLC.8 To the best of our
knowledge, most of the studies were performed on
anthropomorphic phantoms and the studies on
patients did not use patient survival as the gold stan-
dard nor compared the use of a fixed volumes ROI to
that of the more commonly used fixed thresholds ROI
method.
Experiments with an anthropomorphic thorax phan-
tom using SUVs determined in different ROIs, report
that ratios of post-treatment and pretreatment SUVs,
used for response monitoring, were only slightly
dependent on ROI definition, noise and image reso-
lution.14 A false SUV response was observed when
only tumor size changed, but lesion activity was con-
stant, which was caused by partial-volumes effects.14
An almost linear correlation amongst SUVs obtained
with different ROI types was found.15 Not superiori-
ty of any of the evaluated ROIs could be concluded,
since no comparison to a gold standard was made.
Krak et al.16 evaluated chemotherapy in 16 breast
cancer patients by SUV using different ROIs (manual
placement, fixed dimensions [15 mm], threshold based
[50% and 70%] and maximum voxel value). They
found significant lower responses by manually drawn
ROIs as compared to the fixed dimensions ROI. The
relative changes measured by threshold based or max-
imum SUV were similar. They concluded that ROI
definition has a clear effect on measured change in
tumor metabolism and, therefore, that SUVs obtained
from different ROIs cannot be compared to each oth-
er. They, too, were not able to conclude superiority of
any of the evaluated ROIs since they did not com-
pare them to a gold standard or outcome measure.
We are not the first to use change in tumor volume
combined with changes in metabolic activity in
response monitoring. Guillem et al.24 use a technique
previously described by Larson et al.25 to calculate
the change in total lesion glycolysis (δTLG) by multi-
plication of the FDG activity concentration (SUV) to
the tumor metabolic volume in 15 patients with pri-
mary rectal cancer treated with preoperative chemo-
radiotherapy, identifying 100% of responses. They
found complete concordance between pathology and
the δTLG parameter in 6 cases, in 4 the response was
overestimated and in 5 it was underestimated, which
was slightly better than usage of SUVmax or SUVmean
alone. More recently, Benz et al.26 investigated 20
patients with locally advanced high-grade soft tissue
sarcoma that underwent neoadjuvant treatment and
compared SUVmax, SUVmean, TLGmax and TLGmean (using
volumes determined on CT) for response monitor-
ing. They conclude that TLG was less accurate in pre-
dicting tumor response than were measurements of the
intratumoral FDG concentration (SUV). This tech-
nique has been evaluated for treatment of primary
rectal cancer,24, 27, 28 NSCLC,29 malignant mesothe-
lioma,30 melanoma 31 and breast cancer.32 The TLG
has the disadvantage that it is highly dependent on the
threshold level used. When lesion response to treat-
ment causes its metabolic rate to be in the same range
as the background, large-volume ROIs will be derived,
which will artifactually lead to underestimation of
treatment effect. The fixed volumes-ROI technique
has the advantage that in substantial metabolic
response the remaining MRglu can be calculated.
In this study, in CRC and NSCLC, both MRglu esti-
mations showed a significant decrease between base-
line and follow-up FDG-PET as a sign of therapy
response. Significant differences in the degree of rel-
ative MRglu decrease were seen, which was expected
since fixed volumes based ROI-determination also
takes into account tissues with <50% of the maximum
activity in the lesion on follow-up FDG-PET. Thus,
the volume-based average will be lower than the val-
ue determined by using a threshold for ROI definition.
A significant relation between ∆MRglu, fixed volumes and
both overall and progression free survival was shown,
which was still present after correcting for known
confounders. ∆MRglu, fixed thresholds did not show signif-
icant prediction of progression free survival in CRC and
of progression free survival in NSCLC after multivari-
ate correction. Other cut-off values may be necessary
when performing treatment response monitoring by
fixed volumes measurements, since MRglu, fixed volumes
showed higher decreases than MRglu, fixed thresholds as
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explained before. Using the median to dichotomize
∆MRglu showed higher separation of median survival
times between fixed volumes and fixed thresholds in
CRC and highly similar separation in NSCLC.
Threshold methods are relatively simple and user-
independent and recovered counts are relatively inde-
pendent of lesion size and of changes in geometry.
Fixed dimension (15 mm) methods are relatively sim-
ple, semiautomatic and presumably less sensitive to
partial volume effects when tumor size changes dur-
ing therapy. Our presented fixed volumes methods
benefits from the advantages of both and also takes
into account treatment induced changes in tumor size.
Conclusions
Metabolic response has a high predictive value for
treatment outcome in CRC as well as NSCLC patients.
For determination of the ROI in therapy response
monitoring studies the fixed volumes method proved
to be superior to the fixed thresholds method. The use
of one standardized method for ROI definition is of the
utmost importance in future multicenter trials, in order
to avoid institution-based variations in evaluation of
metabolic response.
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